You just read:

FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)

News provided by

Eisai Inc.

Mar 11, 2010, 11:00 ET